Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A very rare lysosomal disease, that has most often been observed in the Middle East, characterized by a progressive slowing of the growth rate in early childhood; stiffness and pain in shoulders, hips, and finger joints; a gradual, mild coarsening of facial features; and by a slower progression, milder clinical course and longer life expectancy than that seen in mucolipidosis II and mucolipidosis III alpha/beta. Cognitive function is normal or only slightly impaired and retinitis pigmentosa has been reported in a few patients. Many survive into early adulthood, but ultimately succumb to cardiorespiratory insufficiency.
Features include always present findings: Flat capital femoral epiphysis, Claw hand deformity, Finger joint contracture, and Excessive inward curvature of the lower spine (hyperlordosis) and others; and common findings: Short stature. 26 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 7 | Flat capital femoral epiphysis, Finger joint contracture, Excessive inward curvature of the lower spine (hyperlordosis) |
Heart and blood vessels | 2 | Aortic valve stenosis, Aortic regurgitation |
Brain and nerves | 2 | Mild intellectual disability, Intellectual disability |
Arms and legs | 2 | Claw hand deformity, Finger joint contracture |
Muscles | 2 | Finger joint contracture, Shoulder contracture |
Eyes | 1 | Opacification of the corneal stroma |
Growth and development | 1 | Short stature |
Head and neck | 1 | Coarse facial features |
Mucolipidosis III gamma (ML III) is a slowly progressive inborn error of metabolism mainly affecting skeletal, joint, and connective tissues. Clinical onset is in early childhood and the progressive course, including mild cardiac involvement, results in severe functional impairment and significant morbidity. A few (probably 10%) affected individuals may display mild cognitive impairment , but the majority do not. The initial manifestation in most affected individuals is joint stiffness in fingers as early as age 18 months . Growth. Weight and length at birth are within normal limits. Gradual slowing of growth rate begins in early childhood. Worsening hip and knee contractures add to the poor growth rate.
Source: GeneReviews — "Mucolipidosis III Gamma"
GNPTG encodes N-acetylglucosamine-1-phosphate transferase subunit gamma (305 aa). Non-catalytic subunit of the N-acetylglucosamine-1-phosphotransferase complex, an enzyme that catalyzes the formation of mannose 6-phosphate (M6P) markers on high mannose type oligosaccharides in the Golgi apparatus. Highest expression in Adrenal Gland (182.3 TPM) and Brain Spinal cord cervical c-1 (117.5 TPM).
GNPTG-mucolipidosis is caused by mutations in the GNPTG gene on chromosome 16.
GNPTG is classified as a druggable target (Druggable Genome and Enzyme categories) with score 0.0.
To date no correlation between severity of disease and type of GNPTG pathogenic variant has been reported; however, predicted loss-of-function variants, such as the recurrent variants , , and , are associated with a severe phenotype . See for more details.
Source: GeneReviews — "Mucolipidosis III Gamma"
Formal diagnostic criteria for mucolipidosis III gamma have not been established.
Mucolipidosis III gamma (ML III) should be suspected in individuals with the following clinical and radiographic findings .
Clinical findings
Growth rate deceleration
Joint stiffness of the fingers, shoulders, and hips
Gradual mild coarsening of facial features
Genu valgum
Spinal deformities including scoliosis and hyperlordosis
No organomegaly
Radiographic findings. In early childhood, skeletal radiographs reveal mild-to-moderate dysostosis multiplex:
Source: GeneReviews — "Mucolipidosis III Gamma"
Mucolipidosis II (ML II), ML III/, and ML III are all UDPGlcNAc 1-P-transferase deficiency disorders . Whereas the clinical phenotypes of ML III/ and ML III can be difficult to distinguish, the severe phenotype of ML II is easily differentiated. In general, the ML III phenotype is less severe than ML III/. See for inherited disorders to consider in the differential diagnosis of ML III. Table 2. Genes to Consider in the Differential Diagnosis of Mucolipidosis III Gamma (ML III)
Gene(s) | Disorder | MOI | Clinical Features of Differential Diagnosis Disorder |
|---|---|---|---|
GNPTAB | ML III/ (See GNPTAB-Related Disorders.)1 | AR | Clinical features of ML III are similar to but milder than those of ML III/. |
Genetic testing for GNPTG is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for GNPTG-mucolipidosis has been reported in the published literature.
No approved treatments are currently available for GNPTG-mucolipidosis. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with mucolipidosis III gamma (ML III), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 3.
Recommended Evaluations Following Initial Diagnosis in Individuals with Mucolipidosis III
System/Concern | Evaluation | Comment
| Height, weight, head circumference | To assess growth rate
| Pain assessment | To assess pain scores involvement
| Orthopedics/ physical medicine rehab/ PT OT eval | Incl assessment of:
Lower limb pain (can be significant)
Gross motor fine motor skills
Hip, knee contractures
Limited range of motion of shoulders
Stiffness of finger joints Dupuytren-like palmar contractures (starting in late childhood)
Carpal tunnel syndrome
Odontoid dysplasia risk of atlanto-axial dislocation
Mobility, ADL, need for adaptive devices
Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills)
Complete skeletal survey | To better assess skeletal involvement
Metabolic
bone disease | DXA study; biomarkers reflecting bone metabolism | Perform baseline DXA scan:
Children age 5 yrs
Adults at time of diagnosis
| Developmental assessment | • Incl motor, adaptive, cognitive, speech-language eval
Eval for early intervention/ special education
| Clinical exam, EKG, echocardiogram | To assess for mitral aortic valve involvement usually beginning in...
Source: GeneReviews — "Mucolipidosis III Gamma"
Vigorous stretching exercises are not recommended because they are ineffective, painful, and may damage the surrounding joint capsule and adjacent tendons.
Source: GeneReviews — "Mucolipidosis III Gamma"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Mucolipidosis III Gamma"
View trials for GNPTG-mucolipidosis
Table 4. Recommended Surveillance for Individuals with Mucolipidosis III
System/Concern | Evaluation | Frequency |
|---|---|---|
Constitutional | Height, weight, head circumference | Yearly |
Pain | Assessment of pain level by pain specialist | Yearly |
Musculoskeletal | Assessment of range of motion, stiffness contractures, carpal tunnel syndrome, tarsal tunnel syndrome, ADL | Yearly |
Mobility | By PT, physiatrist | Yearly |
Fine motor skills | By OT | Yearly Metabolic |
bone disease | DXA scan | Children: 5-yr intervals after baseline study; Adults w/normal studies: 3-yr intervals; Adolescents adults w/ densitometry: 2-yr intervals |
Respiratory | Lung function studies | 5-yr intervals |
Cardiac | Cardiac eval incl echocardiography | Yearly |
Ophthalmologic | Monitor visual acuity corneal opacities. | Yearly Development/ |
School issues | General eval | Yearly Educational |
resources | General eval | Yearly Psychological |
issues | General eval | Yearly Community |
resources | General eval | Yearly ADL = activities of daily living; DXA = dual-energy x-ray absorptiometry; OT = occupational therapist; PT = physical therapist |
Source: GeneReviews — "Mucolipidosis III Gamma"
Phenotype severity distribution: 11 always present features, 1 common feature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for GNPTG-mucolipidosis.
102 publications have been identified in PubMed for GNPTG-mucolipidosis. Research spans Basic Science / Preclinical (76%), Review / Meta-Analysis (10%), and Epidemiology / Natural History (4%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 73 | 76% |
Research summaries | 10 | 10% |
Disease patterns and progression | 4 | 4% |
Testing and diagnosis research | 3 | 3% |
Clinical study results | 3 | 3% |
New treatment approaches | 2 | 2% |
Patient case studies | 1 | 1% |
Madero L (2026). [PMID: 41101460](https://pubmed.ncbi.nlm.nih.gov/41101460/). *Gastroenterol Hepatol*. [Review / Meta-Analysis]
Ravi VR (2026). [PMID: 41542445](https://pubmed.ncbi.nlm.nih.gov/41542445/). *bioRxiv*. [Basic Science / Preclinical]
Thull J (2026). [PMID: 42135595](https://pubmed.ncbi.nlm.nih.gov/42135595/). *Med Phys*. [Clinical Trial Publication]
Slominski AT (2026). [PMID: 41554413](https://pubmed.ncbi.nlm.nih.gov/41554413/). *Biochem Pharmacol*. [Basic Science / Preclinical]
Shao Q (2026). [PMID: 42216814](https://pubmed.ncbi.nlm.nih.gov/42216814/). *Angew Chem Int Ed Engl*. [Basic Science / Preclinical]
Han Z (2026). [PMID: 41255192](https://pubmed.ncbi.nlm.nih.gov/41255192/). *Adv Mater*. [Basic Science / Preclinical]
Habieb ME (2026). [PMID: 41649802](https://pubmed.ncbi.nlm.nih.gov/41649802/). *J Biochem Mol Toxicol*. [Epidemiology / Natural History]
King JL (2026). [PMID: 41439800](https://pubmed.ncbi.nlm.nih.gov/41439800/). *Biotechnol Bioeng*. [Basic Science / Preclinical]
Akram S (2026). [PMID: 33351446](https://pubmed.ncbi.nlm.nih.gov/33351446/). *Unknown Journal*. [Diagnostic / Biomarker]
Wang M (2026). [PMID: 42139975](https://pubmed.ncbi.nlm.nih.gov/42139975/). *Phytomedicine*. [Basic Science / Preclinical]
Data assembled from 8 of 12 sources · Last updated Oct 3, 2026, 8:11 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about GNPTG-mucolipidosis
Progressive pseudorheumatoid dysplasia |
AR |
Joint stiffness osteoarthritis; Spinal involvement (kyphoscoliosis, platyspondyly); Claw hands |
Absence of dysostosis multiplex; Disease course less progressive; Normal level of serum hydrolases |
COL2A1 | Osteoarthritis w/mild chondrodysplasia (See Type II Collagen Disorders Overview.) | AD | Joint stiffness osteoarthritis; Mild short stature |
CTSA | Juvenile galactosialidosis(OMIM 256540) | AR | Joint stiffness; Corneal clouding; Cardiac abnormalities; Facial coarseness; Dysostosis multiplex |
GLB1 | MPS IV B3 (See GLB1-Related Disorders.) | AR | Joint stiffness; Corneal clouding; Cardiac abnormalities; Normal intelligence |
GUSB | MPS VII B4 | AR | Dysostosis multiplex; Spinal deformities (kyphoscoliosis); Coarse facies; Corneal opacities; Cardiac involvement |
IDS | Slowly progressive MPS II5 | XL | Joint stiffness; Corneal clouding; Cardiac abnormalities; Facial coarseness; Dysostosis multiplex |
IDUA | Slowly progressive MPS I6 | AR | Joint stiffness; Corneal clouding; Cardiac abnormalities; Facial coarseness; Dysostosis multiplex |
Alpha-mannosidosis | AR | Facial coarseness; Dysostosis multiplex | Organomegaly; Cognitive impairment; Hearing impairment; Normal level of serum hydrolases SLC17A5 |
Free sialic acid storage disorders | AR | Facial coarseness; Skeletal abnormalities | Organomegaly; Cognitive impairment; Neurologic abnormalities ... |
Source: GeneReviews — "Mucolipidosis III Gamma"